Medaxes Sets Out Hopes For Belgian Biosimilars Taskforce
INAMI Taskforce Met For The First Time In Late January
Belgian off-patent industry association Medaxes has set out its aspirations for a new biosimilars taskforce that has been set up by local health insurance body INAMI. Data cited by the industry body shows that biosimilar penetration in Belgium is still lagging behind that of its European neighbors.
You may also be interested in...
Draft legislation published this month in Belgium offers the country greater guidance that could help boost the uptake of “under-utilized” medicines in hospitals, including biosimilars.
Biosimilars have been given a potential boost in Belgium after the latest agreement between health insurers and prescribing doctors included a commitment to contribute to a biosimilars taskforce aimed at driving uptake. Initially introduced in early 2020, the taskforce is due to be relaunched in 2022.
Attendees to Medicines for Europe’s virtual summit on biosimilars heard how learning from experiences across Europe can allow individual countries to build a toolbox of policies to help create a sustainable biosimilars market.